MAPT and Alzheimer disease: Aβ-positive CBS patients (as determined by cerebrospinal fluid Aβ levels or amyloid-PET, which was available for all CBS cases) were considered to have underlying 3 R/4 R tau AD pathology and were therefore excluded from the current study28.